TTF-1, cytokeratin 7, 34βE12, and CD56/NCAM immunostaining in the subclassification of large cell carcinomas of the lung

被引:69
作者
Rossi, G
Marchioni, A
Milani, M
Scotti, R
Foroni, M
Cesinaro, AM
Longo, L
Migaldi, M
Cavazza, A
机构
[1] Univ Modena, Sect Pathol Anat, Dept Diagnost Lab & Legal Med Serv, I-41100 Modena, Italy
[2] Univ Modena, Sect Resp Dis Clin, Dept Med Sci, I-41100 Modena, Italy
[3] Hosp Faenza, Div Oncol, Faenza, Italy
[4] St Maria Nuova Hosp, Unit Pathol, Reggio Emilia, Italy
关键词
lung; immunohistochemistry; large cell carcinoma; thyroid transcription factor-1; TTF-1; cytokeratins; CD56; classification; gene expression;
D O I
10.1309/9W8D3XCVLRA3858A
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
We selected a 4-stain immunopanel including thyroid transcription factor (TTF)-1, cytokeratin (CK) 7, 34betaE12, and CD56/neural cell adhesion molecule (NCAM) to subclassify a series of 45 pulmonary large cell carcinomas (LCCs) on bronchial biopsy. All cases consisted of a large tumor cell proliferation with abundant cytoplasm, vesicular nuclei, and prominent nucleoli. Immunohistochemically, 27 tumors (60%) were subclassified as adenocarcinoma (TTF-1+/CK7+, 24; CK7+ only, 3), 10 (22%) as squamous cell carcinoma (34betaE12+ only), and 4(9%) as LCC with neuroendocrine differentiation (CD56+, variably stained with TTF-1 and CK7, 34betaE12-). In 4 cases, the tumors coexpressed CK7 and 34betaE12 (3 cases) or were completely unstained (1 case). Surgically resected tumors matched exactly with the corresponding original biopsy specimens in 21 of 23 cases; consistent CD56 expression was a reliable marker in confirming a diagnosis of large cell neuroendocrine carcinoma even on biopsy. Our results suggest that the proposed 4-stain set of commercially available markers might help subclassify LCC even in small biopsy material, validating expression-profiling studies aimed at lung cancer classification and permitting more consistent patient enrollment for trials with targeted treatments.
引用
收藏
页码:884 / 893
页数:10
相关论文
共 58 条
[11]   Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non-small cell category [J].
Edwards, SL ;
Roberts, C ;
McKean, ME ;
Cockburn, JS ;
Jeffrey, RR ;
Kerr, KM .
JOURNAL OF CLINICAL PATHOLOGY, 2000, 53 (07) :537-540
[12]   Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J].
Fukuoka, M ;
Yano, S ;
Giaccone, G ;
Tamura, T ;
Nakagawa, K ;
Douillard, JY ;
Nishiwaki, Y ;
Vansteenkiste, J ;
Kudoh, S ;
Rischin, D ;
Eek, R ;
Horai, T ;
Noda, K ;
Takata, I ;
Smit, E ;
Averbuch, S ;
Macleod, A ;
Feyereislova, A ;
Dong, RP ;
Baselga, J .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2237-2246
[13]   Diversity of gene expression in adenocarcinoma of the lung [J].
Garber, ME ;
Troyanskaya, OG ;
Schluens, K ;
Petersen, S ;
Thaesler, Z ;
Pacyna-Gengelbach, M ;
van de Rijn, M ;
Rosen, GD ;
Perou, CM ;
Whyte, RI ;
Altman, RB ;
Brown, PO ;
Botstein, D ;
Petersen, I .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (24) :13784-13789
[14]   ADENOCARCINOMA AND LARGE CELL UNDIFFERENTIATED CARCINOMA OF THE LUNG [J].
HAMMAR, S .
ULTRASTRUCTURAL PATHOLOGY, 1987, 11 (2-3) :263-291
[15]  
Herbst RS, 2003, CLIN CANCER RES, V9, P5813
[16]   LARGE CELL-CARCINOMA OF THE LUNG - PROGNOSTIC IMPLICATIONS OF HISTOPATHOLOGIC AND IMMUNOHISTOCHEMICAL SUBTYPING [J].
ISHIDA, T ;
KANEKO, S ;
TATEISHI, M ;
OKA, T ;
MITSUDOMI, T ;
SUGIMACHI, K ;
HARA, N ;
OHTA, M .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1990, 93 (02) :176-182
[17]   hASH1 expression is closely correlated with endocrine phenotype and differentiation extent in pulmonary neuroendocrine tumors [J].
Jiang, SX ;
Kameya, T ;
Asamura, H ;
Umezawa, A ;
Sato, Y ;
Shinada, J ;
Kawakubo, Y ;
Igarashi, T ;
Nagai, K ;
Okayasu, I .
MODERN PATHOLOGY, 2004, 17 (02) :222-229
[18]   Two prognostically significant subtypes of high-grade lung neuroendocrine turnours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles [J].
Jones, MH ;
Virtanen, C ;
Honjoh, D ;
Miyoshi, T ;
Satoh, Y ;
Okumura, S ;
Nakagawa, K ;
Nomura, H ;
Ishikawa, Y .
LANCET, 2004, 363 (9411) :775-781
[19]   A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung [J].
Kato, H ;
Ichinose, Y ;
Ohta, M ;
Hata, E ;
Tsubota, N ;
Tada, H ;
Watanabe, Y ;
Wada, H ;
Tsuboi, M ;
Hamajima, N ;
Ohta, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (17) :1713-1721
[20]  
Kaufmann O, 2001, AM J CLIN PATHOL, V116, P823